Form 4: Lexicon Pharmaceuticals Director Sobecki Reports Stock Transactions

Director Christopher J. Sobecki reports the acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on April 28, 2024.

Summary

• On April 28, 2024, Christopher J. Sobecki, a director of Lexicon Pharmaceuticals, reported transactions involving the company's stock.
• Sobecki acquired 8,032 shares of common stock at a price of $0.
• He also disposed of 8,032 shares of common stock.
• Following these transactions, Sobecki beneficially owns 167,055 shares of Lexicon Pharmaceuticals.
• The transactions involved the vesting of restricted stock units, each representing a contingent right to receive one share of common stock.
• The restricted stock units vest 100% on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key individuals within Lexicon Pharmaceuticals.

Stakeholder Impact

• Shareholders can use this information to understand the trading activity of a key insider.

Key Dates